Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : N::A tags : Phase 1 save search
Cybin Announces Positive Data from its CYB003 Phase 1/2a Trial and Provides Update on its CYB004 Development Program
Published: 2023-02-28 (Crawled : 14:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: 2.11%
H: 4.93%
C: -9.06%
cyb003 program cyb004 trial positive update psilocybin phase 1
Cybin Provides Progress Update on its CYB004-E Phase 1 Trial
Published: 2022-11-10 (Crawled : 18:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: -3.37%
H: 12.39%
C: 2.04%
cyb004 trial update phase 1
MindMed Collaborators Initiate Phase 1 Comparative PK/PD Trial of R-, S- and Racemic MDMA
Published: 2022-10-04 (Crawled : 12:00) - prnewswire.com
MNMD | $9.78 1.14% 1.23% 1.1M
|
n/a
|
| O: 1.21%
H: 4.78%
C: 4.48%
trial phase 1
MindMed Collaborators Dose First Subject in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
Published: 2022-09-20 (Crawled : 12:00) - mindmed.co
MNMD | $9.78 1.14% 1.23% 1.1M
|
n/a
|
| O: -0.68%
H: 0.41%
C: -4.76%
trial phase 1
MindMed Collaborators Dose First Patient in Phase 1 Investigator-Initiated Trial of MDMA-Like Substances
Published: 2022-09-20 (Crawled : 12:00) - biospace.com/
MNMD | $9.78 1.14% 1.23% 1.1M
|
n/a
|
| O: -0.68%
H: 0.41%
C: -4.76%
trial phase 1
Cybin Inc. Announces First Participants Dosed in its Phase 1/2a Trial of CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-08-30 (Crawled : 12:20) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: -1.89%
H: 4.81%
C: 4.81%
cyb003 treatment trial phase 1 major depressive disorder
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
Published: 2022-08-17 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: 4.72%
H: 3.7%
C: -2.47%
cyb003 license granted trial phase 1
Clinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-07-12 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: -0.69%
H: 0.87%
C: -0.3%
cyb003 treatment drug trial corporation phase 1 major depressive disorder
Cybin Completes Acquisition of Phase 1 DMT Study from Entheon Biomedical
Published: 2022-07-11 (Crawled : 12:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: 3.23%
H: 0.0%
C: -9.53%
acquisition study phase 1
Cybin Receives FDA IND Clearance for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Potential Treatment of Major Depressive Disorder
Published: 2022-06-27 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: 0.44%
H: 8.47%
C: 4.24%
cyb003 treatment fda clearance trial potential phase 1 major depressive disorder
Cybin Receives Institutional Review Board Approval for its Phase 1/2a Clinical Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-06-09 (Crawled : 22:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: 2.23%
H: 0.51%
C: -10.52%
cyb003 treatment trial approval review phase 1 major depressive disorder
Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-05-31 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: 6.13%
H: 3.93%
C: 0.0%
cyb003 treatment fda application trial phase 1 major depressive disorder
MindMed Reports Topline Data From Phase 1 Trial of MM-110 in Development for the Treatment of Opioid Withdrawal
Published: 2022-05-19 (Crawled : 20:00) - biospace.com/
MNMD | $9.78 1.14% 1.23% 1.1M
|
n/a
|
| O: 0.56%
H: 3.52%
C: -0.95%
mm-110 treatment opioid topline trial phase 1
Genenta Progresses to Higher Dosing Cohort in Temferon™ Phase 1/2a Clinical Trial in Glioblastoma Multiforme
Published: 2022-05-04 (Crawled : 12:00) - biospace.com/
GNTA | $3.4423 -0.69% 0.8% 2.1K
|
n/a
|
| O: 4.19%
H: 1.73%
C: -2.1%
trial phase 1 glioblastoma
Alzamend Neuro Announces $4 Million Additional Investment from Digital Power Lending Upon Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
NILE 4 | $0.1225 0.0%
|
n/a
|
| O: -2.93%
H: 3.88%
C: 0.64%
ALZN | $0.741 -12.82% -10.29% 120K
|
Professional, Scientific, and T...
|
| O: 5.59%
H: 1.6%
C: -2.25%
al001 treatment dementia trial alzheimer’s phase 1 alzheimer's
BitNile Holdings Announces Additional Investment in Alzamend From Completion of Phase 1 First-in-Human Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer’s
Published: 2022-04-28 (Crawled : 11:00) - biospace.com/
NILE 4 | $0.1225 0.0%
|
n/a
|
| O: -2.93%
H: 3.88%
C: 0.64%
ALZN | $0.741 -12.82% -10.29% 120K
|
Professional, Scientific, and T...
|
| O: 5.59%
H: 1.6%
C: -2.25%
al001 treatment dementia trial alzheimer’s phase 1 alzheimer's
Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
Published: 2022-04-21 (Crawled : 13:00) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: -1.7%
H: 0.0%
C: 0.0%
cyb003 treatment drug trial corporation phase 1 major depressive disorder
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003 Supporting Advancement into Phase 1/2a Clinical Trial
Published: 2022-03-29 (Crawled : 12:20) - biospace.com/
CYBN | $0.3708 1.31% -4.32% 2.7M
|
n/a
|
| O: 1.3%
H: 2.56%
C: 1.85%
cyb003 trial preclinical pre-clinical phase 1 psilocybin
Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial
Published: 2022-03-02 (Crawled : 08:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: -8.79%
cyad-101 clinical hold phase 1b trial cel phase 1 phase 2b
Celyad Oncology Announces Voluntary Pause of CYAD-101-002 Phase 1b Trial
Published: 2022-02-28 (Crawled : 08:00) - globenewswire.com
CYAD | $0.47 -12.49% 49K
|
Health Technology
|
| O: -10.87%
H: 0.7%
C: -6.97%
cyad-101 phase 1b trial cel phase 1 phase 2b
Gainers vs Losers
| 48% | 52% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.